Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesCancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533724

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533724

Cancer Vaccines

PUBLISHED:
PAGES: 403 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Cancer Vaccines Market to Reach US$14.8 Billion by 2030

The global market for Cancer Vaccines estimated at US$7.9 Billion in the year 2023, is expected to reach US$14.8 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2023-2030. Preventive Vaccine, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$7.6 Billion by the end of the analysis period. Growth in the Therapeutic Vaccine segment is estimated at 10.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 12.9% CAGR

The Cancer Vaccines market in the U.S. is estimated at US$2.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.1 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Key Trends and Drivers

Cancer vaccines represent a significant advancement in oncological medicine, offering potential for both the prevention and treatment of various forms of cancer. These vaccines work by stimulating the immune system to attack cells that display tumor-specific antigens, thereby preventing these cells from developing into full-blown cancers or eradicating existing tumors. Preventative vaccines, such as those developed for human papillomavirus (HPV) which is linked to cervical, anal, and other cancers, have already demonstrated efficacy in reducing cancer risk among vaccinated populations. Therapeutic cancer vaccines, on the other hand, are used to treat existing cancers by strengthening the body's immune response to fight the cancer cells. Several therapeutic vaccines are in clinical trials, targeting a range of cancers including melanoma, prostate, lung, and breast cancers.

The development and enhancement of cancer vaccines involve intricate biotechnological advancements and significant research investments. Molecular techniques such as gene sequencing and bioinformatics are crucial in identifying tumor-specific antigens and developing vaccines that can target them effectively. Modern biotechnology has also enabled the design of personalized vaccines that are tailored to the unique genetic makeup of an individual’s tumor, thereby increasing the effectiveness of the treatment. Furthermore, innovations such as the use of viral vectors, dendritic cell vaccines, and RNA technology have expanded the potential of therapeutic cancer vaccines. These advances have been supported by a robust clinical trial infrastructure that allows for the rapid assessment and optimization of vaccine formulations and dosing schedules, ensuring that only the most effective treatments reach patients.

The growth in the cancer vaccine market is driven by several factors, including the increasing incidence of cancer worldwide, the rising demand for personalized medicine, and substantial investments in healthcare infrastructure supporting immunotherapy. As cancer remains a leading cause of death globally, governments and healthcare organizations are emphasizing early detection and prevention, which bolsters the market for preventive vaccines. In parallel, the therapeutic cancer vaccine sector benefits from the growing number of cancer patients who require effective treatment after diagnosis. Technological advancements in vaccine development platforms and adjuvant systems continue to enhance the efficacy and safety profiles of cancer vaccines, making them more appealing to both healthcare providers and patients. Additionally, the growing public awareness about the potential of immunotherapy in treating cancer, coupled with increasing healthcare spending in emerging economies, is propelling market growth. Market expansion is further supported by strategic collaborations between biopharmaceutical companies aiming to accelerate the development and commercialization of new vaccines. These drivers ensure the sustained growth of the cancer vaccine industry, reflecting its critical role in modern oncological therapeutics and preventive healthcare.

Select Competitors (Total 61 Featured) -

  • Agenus Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics Inc.
  • F. Hoffmann-La Roche Ltd
  • Genexine Inc.
  • Gritstone bio
  • ImmunityBio, Inc.
  • Immutep Ltd
  • ISA Pharmaceuticals B.V.
  • Merck & Co. Inc.
  • Northwest Biotherapeutics Inc.
  • OncBioMune Pharmaceuticals Inc.
  • Oncovir Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.;
Show more
Product Code: MCP27117

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Cancer Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Cancer Worldwide
    • Advances in Immunotherapy
    • Rising Investment in Cancer Research
    • Growing Adoption of Personalized Medicine
    • Development of Novel Cancer Vaccines
    • Favorable Government Initiatives and Funding
    • Increasing Awareness and Screening Programs
    • Advances in Vaccine Delivery Technologies
    • Expansion of Clinical Trials and Research Studies
    • Increasing Demand for Prophylactic Vaccines
    • Rising Incidence of Virus-Associated Cancers
    • Collaborations and Partnerships Among Pharmaceutical Companies
    • Technological Innovations in Vaccine Development
    • Regulatory Approvals and Accelerated Pathways
    • Growing Importance of Biomarkers in Vaccine Development
    • Challenges in Vaccine Manufacturing and Distribution
    • Patient Access and Reimbursement Issues
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cancer Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cancer Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Preventive Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Preventive Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Preventive Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Therapeutic Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Therapeutic Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Therapeutic Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Bladder Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Bladder Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Bladder Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Melanoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cervical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cervical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cervical Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Prostate Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Prostate Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Prostate Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Recombinant Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Recombinant Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Recombinant Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Viral Vector & DNA Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Viral Vector & DNA Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Viral Vector & DNA Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Whole-Cell Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Whole-Cell Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Whole-Cell Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • JAPAN
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • CHINA
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: China 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • EUROPE
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Cancer Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Cancer Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • FRANCE
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: France 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • GERMANY
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Cancer Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • INDIA
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: India 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Cancer Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Cancer Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Cancer Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Cancer Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030
  • AFRICA
    • Cancer Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Cancer Vaccines by Vaccine Type - Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Cancer Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Preventive Vaccine, Therapeutic Vaccine and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Cancer Vaccines by Application - Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Cancer Vaccines by Application - Percentage Breakdown of Value Sales for Bladder Application, Melanoma Application, Other Applications, Cervical Application and Prostate Application for the Years 2014, 2024 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Cancer Vaccines by Technology - Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Cancer Vaccines by Technology - Percentage Breakdown of Value Sales for Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology and Other Technologies for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!